| Literature DB >> 32615671 |
Kwang Jin Ko1, Kyu-Sung Lee2,3.
Abstract
Abdominal sacrocolpopexy is the gold-standard treatment for apical compartment prolapse, as it is more effective and durable than the transvaginal approach. In the current era of minimally invasive surgery, laparoscopic sacrocolpopexy techniques have been described, but have not gained popularity due to their complexity and steep learning curves. To overcome this problem, robotic sacrocolpopexy was introduced, and has shown equivalent outcomes and safety compared to open and laparoscopic sacrocolpopexy based on findings that have been accumulated over 15 years.Entities:
Keywords: Pelvic organ prolapse; Robotics; Sacrocolpopexy
Year: 2020 PMID: 32615671 PMCID: PMC7332820 DOI: 10.5213/inj.2040056.028
Source DB: PubMed Journal: Int Neurourol J ISSN: 2093-4777 Impact factor: 2.835
Surgical procedure and materials used in robotic sacrocolpopexy
| Study | Mesh | Depth of vaginal dissection | Type of suture in vagina | Attachment to sacrum | Peritonealization | Concurrent operation | Operative time (min), mean or median (range) |
|---|---|---|---|---|---|---|---|
| Elliott et al. [ | Y-shaped PP, IntePro, AMS | As distal as possible | PTFE, interrupted | PTFE, interrupted | NR | Anti-incontinence: 52% | 186 (129–285) |
| Benson et al. [ | Y-shaped PP, IntePro, AMS | NR | 2-0, interrupted | 2-0 polyglactin, interrupted | 3-0 polyglactin, running | NR | 194 (137–280) |
| Xylinas et al. [ | Y-shaped PP, Gynemesh, Ethicon | NR | 2-0 PP, interrupted | 2-0 PP, interrupted | 2-0 polyglactin, running | Anti-incontinence: 50% | 144 (120–180) |
| Tan-Kim et al. [ | Y-shaped PP, Gynemesh, Ethicon | At least 4 cm down | 2-0 PP, interrupted | 2-0 PP, interrupted | 2-0 polyglactin, running | Anti-incontinence: 21% | 281 |
| Posterior repair: 7% | |||||||
| Paraiso et al. [ | Two separate PP (unspecified) | NR | NR | Non-absorbable or Tacker | NR | NR | 257 (191–381) |
| Seror et al. [ | Y-shaped PP, Parietex, Tyco | NR | 2-0 PP, interrupted | Mersuture | 2-0 polyglactin, running | Anti-incontinence: 30% | 125 (90–270) |
| Siddiqui et al. [ | Y-shaped PP, Intepro Lite, AMS | NR | NR | NR | NR | Anti-incontinence: 42% | NR |
| Posterior colporrhaphy: 8% | |||||||
| Belsante et al. [ | Two separate PP, Marlex, Bard | Anterior: distally to above the level of the trigone (3–5 cm distal to the vaginal apex) | 2-0 polyglactin, interrupted | 2-0 PE | 2-0 polyglactin, running | NR | 288 (210–390) |
| Posterior: down as distally as possible | |||||||
| Louis-Sylvestre and Herry [ | Two separate PE, Mersuture, Ethicon | NR | 3-0 polyester | Nonabsorbable (unspecified) | NR | NR | 246 (180–415) |
| Salamon et al. [ | Y-shaped PP, Restorelle Y SmartmeshTM, Coloplast | Anterior: within 1 cm from the bladder neck (4–6 cm anterior coverage) | PTFE, interrupted | PE | Poliglecaprone | Anti-incontinence: 70% | 161 |
| Posterior: level of the perineal body (8–10 cm posterior coverage) | Perineorrhaphy: 22% | ||||||
| Anger et al. [ | Two separate PP (unspecified) | NR | PTFE, interrupted | PTFE | Surgeon preference | NR | 202.8 |
| Barboglio et al. [ | Y-shaped PP, IntePro, AMS | NR | PTFE, interrupted | PE | Polyglactin 910 | NR | 124.2 |
| Culligan et al. [ | Y-shaped PP, Alyte, Bard | Anterior: trigone | PTFE, interrupted | PE | Poliglecaprone (Monocryl) | Anti-incontinence: 81.3% | 148 (75–250) |
| Posterior: perineum | Perineorrhaphy: 11.3% | ||||||
| Sung et al. [ | Two separate PP, Gynemesh, Ethicon | NR | PE | PE | Absorbable | Anti-incontinence: 50% | 251 |
| Vault prolapse: Two separate, Y-fashioned | Cystocele repair (4-arm TO mesh): 6.3% | ||||||
| Uterine-preserving: anterior - 4×5 cm rectangular //posterior - T-shaped | |||||||
| Jong et al. [ | Two-separate PP (Y-fashion), Marlex (Bard) or Atrium (Hudson) | NR | Polyglactin | Nonabsorbable (unspecified) | NR | Lysis of adhesion (n = 7), caruncle (n = 1), fulguration of trigone (n = 1) | 234 |
| van Zanten et al. [ | Y-shaped PP, Prolene (Ethicone) or Restorelle (Coloplast) | NR | PE or PTFE | PTFE or Tacker | Polyglycolic barbed, continuous | RSC: anti-incontinence: 2.1%, AC: 3.2%, PC: 1.6% | 145.3 |
| RSHS: anti-incontinence: 9.4%, AC: 11.1%, PC: 4.3% | 183.1 | ||||||
| Linder et al. [ | Y-shaped PP, IntePro, AMS | Anterior: immediately proximal to trigone | PTFE | PTFE | Absorbable | Anti-incontinence: 78.6% | 160 |
| Posterior: midpoint of posterior vaginal wall | |||||||
| Shimko et al. [ | Y-shaped PP, IntePro, AMS | As distal as possible | PTFE | NR | NR | Anti-incontinence: 60% | 186 |
| Illiano et al. [ | Vault prolapse: two separate PP (rectangular) (unspecified) | As far caudal as possible | Absorbable (unspecified) | PP | Absorbable, running | Never perform | 234.4 |
| Uterine preserving: Y-shaped PP (unspecified) | Anterior: down to the bladder neck | ||||||
| Posterior: down to level of the levator ani | |||||||
| Authors | We use Y-shaped PVDF, DynaMesh-PRS, | Polyglycolic barbed, continuous | PP | Polyglycolic barbed, continuous | |||
| FEG Textiltechnik mbH in case of either vault prolapse or uterine-preserving surgery |
AC, anterior colporrhaphy; NR, not reported; PC, posterior colporrhaphy; PE, polyester; PP, polypropylene; PTFE, polytetrafluoroethylene; PVDF, polyvinylidene fluoride; RSC, robotic sacrocolpopexy; RSHS, robotic supracervical hysterectomy with sacrocervicopexy.
Fig. 1.Vaginal wall dissection (posthysterectomy vaginal vault prolapse). (A) Surgical anatomy of the vaginal apex and bladder, (B, C) anterior vaginal wall dissection (black arrow: vesicovaginal junction), and (D) posterior vaginal wall dissection.
Fig. 2.Fixation of the distal mesh arms to (A, B) the anterior vaginal wall and (C) the posterior vaginal wall using a barbed, delayed-absorbable suture (V-Loc 180; Covidien, Walpole, MA, USA) in a continuous manner. (D) The proximal arm of the mesh passes through the posterior peritoneum (yellow arrow).
Fig. 3.Vaginal wall dissection in sacrohysteropexy (uterus-preserving). (A) Surgical anatomy of the vaginal apex and bladder. (B) Anterior vaginal wall dissection. (C) Posterior vaginal wall dissection. (D) The anterior mesh arm is tunneled through the right broad ligament. Fixation of the distal mesh arms to (E) the posterior vaginal wall and (F) the anterior vaginal wall using a barbed, delayed-absorbable suture (V-Loc 180; Covidien, Walpole, MA, USA) in a continuous manner.
Fig. 4.Fixation of the proximal arm of the mesh. (A) At this time, the tension of the mesh should be adjusted while the vagina is restored using a vaginal manipulator. (B) The mesh is sutured to the anterior longitudinal ligament overlying the sacrum with 2–3 sutures. (C) Reperitonealization after fixation of the mesh using a barbed, delayed-absorbable suture (V-Loc 180; Covidien, Walpole, MA, USA) in a continuous manner.
Study design, demographics, and objective outcomes
| Study | Year | Preoperative POP grade | Cases | Previous hysterect omy (%) | Concurrent hysterectomy, supracervical hysterectomy, or uterine preservation: % | Mean or median follow-up (mo) | Mean age (yr) | Cure rate (%) | Recurrence (%) | Reoperati on rate (%) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall | Apical | Anterior | Posterior | |||||||||||
| RCTs | ||||||||||||||
| Paraiso et al. [ | 2011 | POP-Q stage 2–4 | 40 RSCs/38 LSCs | 100/100 | - | 12 | 61/60 | 88/91 | NR | NR | NR | 0 | 0 | |
| Anger et al. [ | 2014 | POP-Q stage 2–4 | 40 RSCs/38 LSCs | 35/50 | Supracervical hysterectomy: 63 | 6 | 58.5/60.6 | NR | Point C: -7.97/ | Point Ba: -2.48/ | Point Bp: -2.33/ | NR | NR | |
| Supracervicalhysterectomy:53 | Point C: -7.30 | Point Ba: -2.43 | Point Bp: -2.63 | |||||||||||
| Kenton et al. [ | 2016 | POP-Q stage 2–4 | 40 RSCs/38 LSCs | 35/50 | Supracervical hysterectomy: 63 | 12 | 58.5/60.6 | NR | Point C: -7.6/ | Point Ba: -2.2/ | Point Bp: -2.2/ | 0 | 0 | |
| Supracervical hysterectomy: 53 | Point C: -8.7 | Point Ba: -2.5 | Point Bp: -2.4 | |||||||||||
| Illiano et al. [ | 2019 | POP-Q stage 3–4 | 49 RSCs/51 LSCs | 71.4/70.6 | All uterine preservation cases | 25.7/25.1 | 60.2/60.3 | NR | 100/100 | 90/85 | 98/90 | 0 | 0 | |
| Prospective studies | ||||||||||||||
| Moreno et al. [ | 2011 | Vault prolapse, grade 3–4 cystocele | 31 RSCs | 41.9 | NR | 24.5 | 65.2 | NR | NR | NR | NR | 0 | 0 | |
| Seror et al. [ | 2012 | Baden-Walker grade 2–4 | 20 RSC/47 LSC | 9.0 | NR | 15/18 | 60.0/66.7 | NR | 98.5 | NR | NR | 5.0/0 | 0 | |
| Salamon et al. [ | 2013 | POP-Q stage 2–4 | 120 RSCs | 26.7 | All supracervical hysterectomy | 12 | 56.6 | NR | 89 | NR | NR | 0.8 | 0 | |
| Culligan et al. [ | 2014 | Mean POP-Q 2.7 | 143 RSCs | 22 | All supracervical hysterectomy | 12 | 58.6 | 84 | 99.3 | 89.5 | 95.1 | NR | NR | |
| van Zanten F et al. [ | 2019 | POP-Q stage 2-4 | 188 RSC/117 RSHS | 100/0 | - | 12.6/14.8 | 63.1/59.9 | 67.1/64.8 | 91.4/99 | 84.3/77.1 | 95.7/92.4 | Apical: 0.7/0.0 | 22.9/3.7 | |
| All supracervical hysterectomy | Anterior: 15.7/22.9 | |||||||||||||
| Posterior: 4.3 /7.6 | ||||||||||||||
| Multiple: 7.9 /1.0 | ||||||||||||||
| Retrospective studies | ||||||||||||||
| Elliott et al. [ | 2006 | Baden-Walker grade 4 | 30 RSCs | 100 | - | 24 | 67 | NR | 95 | NR | NR | Apical: 3.3 | 6.7 | |
| Posterior: 3.3 | ||||||||||||||
| Benson et al. [ | 2010 | Baden-Walker grade 3-4 | 33 RSCs | 63.6 | All supracervical hysterectomy | 32 | 62 | NR | 97 | NR | NR | Apical: 3.0 | 3.0 | |
| Xylinas et al. [ | 2010 | POP-Q stage 3-4 | 12 RSCs | 8 | NR | 19.1 | 57.1 | NR | 100 | NR | NR | 0 | 0 | |
| Tan-Kim et al. [ | 2011 | Mean C point 0 | 43 RSCs/61 LSCs | 100 | - | 6 | 60/65 | NR | 100/100 | 97.5/89 | 92.5/91 | Anterior: 2.5/11.0 | NR | |
| Posterior: 7.5/9.0 | ||||||||||||||
| Shimko et al. [ | 2011 | Baden-Walker grade 3-4 | 40 RSCs | 100 | - | 62 | 67 | NR | 100 | NR | NR | Anterior: 2.5 | 5 | |
| Posterior: 5.0 | ||||||||||||||
| Siddiqui et al. [ | 2012 | POP-Q stage 2-4 | 125 RSCs/322 ASCs | NR | Supracervical hysterectomy: 46.4 | 18.3/11.7 | 59.5/60.9 | 92.0/96.0 | 94.0/94.0 | NR | NR | Posterior: 2.4 | 2.4/1.6 | |
| Supracervical hysterectomy: 1.0 | Anterior or posterior: 1.6 | |||||||||||||
| Belsante et al. [ | 2013 | Mean C point -1.1 | 35 RSCs | 97 | Supracervical hysterectomy: 17 | 28 | 65 | NR | 100 | NR | NR | Anterior: 5.7 | 0 | |
| Posterior: 2.9 | ||||||||||||||
| Louis-Sylvestre et al. [ | 2013 | POP-Q stage 3-4 | 90 RSCs | 7.8 | Supracervical hysterectomy: 59 | 16.5 | 60.9 | NR | 100 | 94.4 | 98.9 | 0 | 0 | |
| Uterine preservation: 41 | ||||||||||||||
| Barboglio et al. [ | 2014 | Baden-Walker grade 2-4 | 127 RSCs | 42 | Supracervical hysterectomy: 53 | 12 | 59 | 92 | 100 | 92.2 | 88 | Anterior: 1.6 | 1.6 | |
| Sung et al. [ | 2017 | POP-Q stage 2-4 | 16 RSCs | 31.3 | All uterine preservation | 25.3 | 65 | NR | 100 | NR | NR | NR | NR | |
| Linder et al. [ | 2017 | Median POPstage3 | 132 RSCs | 100 | - | 33 | 61.1 | NR | 98.5 | NR | NR | Anterior: 3.0 | 7.6 | |
| Apical: 3.0 | ||||||||||||||
| Posterior: 1.5 | ||||||||||||||
| Unknown: 1.5 | ||||||||||||||
| Jong et al. [ | 2018 | NR | 30 RSCs | 93 | All supracervical hysterectomy | 64 | 64.3 | NR | 93.3 | 90 | 96.7 | Anterior: 10.0 | 13.0 | |
| Apical: 6.7 | ||||||||||||||
| Posterior: 3.3 | ||||||||||||||
RCT, randomized controlled trial; ASC, open abdominal sacrocolpopexy; LSC, laparoscopic sacrocolpopexy; NR, not reported; POP, pelvic organ prolapse; POP-Q, Pelvic Organ Prolapse Quantification System; RSC, robotic sacrocolpopexy; RSHS, robotic supracervical hysterectomy with sacrocervicopexy.
Postoperative complications
| Study | Year | Design | No. | Mesh extrusion/erosion (%) | Bladder injury (%) | Bowel injury | Vascular injury/bleeding (%) | Bowel obstruction/ileus (%) | Others (%) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Elliott et al. [ | 2006 | R | 30 | 6.7 | 0 | 0 | 0 | 0 | 0 | 0 | Mild port site infection (6.7) |
| Benson et al.[ | 2010 | R | 33 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | None |
| Xylinas et al. [ | 2010 | R | 12 | 0 | 0 | 0 | 0 | 0 | NR | NR | None |
| Tan-Kim et al. [ | 2011 | R | 43 | 5 | 2.3 | 2.3 | 2.3 | 0 | NR | NR | Electrolyte imbalance (2.3), trocar site cellulitis (2.3) |
| Paraiso et al. [ | 2011 | RCT | 40 | NR | 6 | 6 | 0 | 6 | NR | NR | Corneal abrasion (3), UTI (14), wound infection (6), abdominal pain (9), abscess (3) |
| Shimko et al. [ | 2011 | R | 40 | 5 | 0 | 0 | 0 | 0 | 16 | NR | Mild port site infection (5), vaginal bleeding (5), port site hernia (5) |
| Moreno et al. [ | 2011 | P | 31 | 0 | 3.2 | 3.2 | 0 | 0 | NR | NR | Vaginal injury (3.2), port infection (3.2), AMI (3.2) |
| Seror et al. [ | 2012 | P | 20 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Constipation (5), UTI (5) |
| Siddiqui et al. [ | 2012 | R | 125 | 2.4 | 1.6 | 1.6 | 0 | 5.6 | NR | NR | Febrile morbidity (4.8%), wound infection (4.9), deep vein thrombosis (0.8), pneumonia (1.6) |
| Belsante et al. [ | 2013 | R | 35 | 3 | 0 | 0 | 0 | 0 | 2 | 0 | Vaginal injury (14) |
| Louis-Sylvestre et al. [ | 2013 | R | 90 | 1 | 2.9 | 1.1 | 0 | 0 | 0 | 0 | Vaginal injury (1.1), trocar site herniation (2.2) |
| Salamon et al. [ | 2013 | P | 120 | 0 | 0 | 0 | 0 | 0.8 | 4.1 | 2.6 | None |
| Anger et al. [ | 2014 | RCT | 40 | 0 | 0 | 0 | 0 | 2.5 | NR | NR | Pulmonary embolism (2.5) |
| Barboglio et al. [ | 2014 | R | 127 | 2.4 | 0 | 2.4 | 0.8 | 1.6 | NR | NR | Port site wound infection (1.6), voiding dysfunction (7.0) |
| Culligan et al. [ | 2014 | P | 143 | 0 | 0 | 0 | 0 | 0 | 0 | 4.7 | None |
| Kenton et al. [ | 2016 | RCT | 40 | 0 | 0 | 0 | 0 | 5 | NR | NR | Port site hernia (2.5) |
| Sung et al. [ | 2017 | R | 16 | 0 | 0 | 0 | 6.3 | 0 | 40 | NR | Headache (6.3), nausea (6.3), transient nerve palsy (6.3) |
| Linder et al. [ | 2017 | R | 132 | 6.1 | NR | NR | NR | NR | NR | NR | None |
| Jong et al. [ | 2018 | R | 56 | 3 | 0 | 0 | 0 | 0 | 1.8 | NR | Vaginal injury (5.4) |
| van Zanten et al. [ | 2019 | P | 305 | 2.1 | 3.2 | 0.3 | 1.1 | 0 | NR | NR | Vaginal injury (0.5), ureteric injury (0.5), incisional hernia (0.3), CVA (0.3) |
| Illiano et al. [ | 2019 | RCT | 49 | 4.1 | 0 | 0 | 0 | 0 | 4.1 | NR | Fever (2.0), nausea and vomiting (16.3), |
AMI, acute myocardial infarction; CVA, cerebrovascular accident; NR, not reported; R, retrospective; RCT, randomized controlled trial; P, prospective; SUI, stress urinary incontinence; UTI, urinary tract infection.